Type 1 Diabetes - Pipeline Insight, 2024

This Type 1 Diabetes - Pipeline Insight, 2024,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Type 1 Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Type 1 Diabetes Understanding

Type 1 Diabetes: Overview

Type 1 diabetes (also known as diabetes mellitus) is an autoimmune disease in which immune cells attack and destroy the insulin-producing cells of the pancreas.

Type 1 diabetes mellitus (T1DM) is an autoimmune disease that leads to the destruction of insulin-producing pancreatic beta cells. Insulin is an essential anabolic hormone that exerts multiple effects on glucose, lipid, protein, and mineral metabolism, as well as growth. Importantly, insulin allows glucose to enter muscle and adipose cells, stimulates the liver to store glucose as glycogen and synthesize fatty acids, stimulates the uptake of amino acids, inhibits the breakdown of fat in adipose tissue, and stimulates the uptake of potassium into cells. Individuals with type 1 diabetes mellitus require life-long insulin replacement therapy. Without insulin, diabetic ketoacidosis (DKA) develops and is life-threatening.

The development of T1DM occurs in 3 stages. Stage 1 is asymptomatic and characterized by normal fasting glucose, normal glucose tolerance, and the presence of greater than or equal to 2 pancreatic autoantibodies. Stage 2 diagnostic criteria include the presence of greater than or equal to 2 pancreatic autoantibodies and dysglycemia: impaired fasting glucose (glucose of 100 to 125 mg/dl) or impaired glucose tolerance (2-hour PG of 140 to 199 mg/dL) or a hemoglobin A1c between 5.7% to 6.4%. Individuals remain asymptomatic. In stage 3, there is diabetes or hyperglycemia with clinical symptoms and two or more pancreatic autoantibodies.

Type 1 Diabetes - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Type 1 Diabetes pipeline landscape is provided which includes the disease overview and Type 1 Diabetes treatment guidelines. The assessment part of the report embraces, in depth Type 1 Diabetes commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Type 1 Diabetes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence R&D Type 1 Diabetes. The therapies under development are focused on novel approaches to treat/improve Type 1 Diabetes.

Type 1 Diabetes Emerging Drugs

Teplizumab: Prevention Bio
Teplizumab is an investigational anti-CD3 monoclonal antibody (mAb) being developed for the delay of clinical type 1 diabetes (T1D) in at-risk individuals. In the pivotal TN-10 Study, a single 14-day course of teplizumab delayed insulin-dependent, clinical-stage disease by a median of at least two years in presymptomatic patients with Stage 2 T1D compared to placebo. The observed adverse events were mechanism-based, transient, and predictable, including lymphopenia, transaminase elevations, rash, and cytokine release events.

Emricasan: Histogen
Emricasan is a potential first-in-class, orally active, pan-caspase inhibitor designed to reduce the activity of enzymes that mediate inflammation and apoptosis. Histogen acquired certain rights to emricasan and other caspase inhibitor compounds as a part of its merger with Conatus Pharmaceuticals Inc. in 2020.

VX-880: Vertex Pharmaceuticals
VX-880 is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology. VX-880 is being evaluated for patients who have T1D with impaired hypoglycemic awareness and severe hypoglycemia. VX-880 has the potential to restore the body’s ability to regulate glucose levels by restoring pancreatic islet cell function, including glucose-responsive insulin production. VX-880 is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection

Type 1 Diabetes: Therapeutic Assessment

This segment of the report provides insights about the Type 1 Diabetes drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Type 1 Diabetes

There are approx. 100+ key companies which are developing the therapies Type 1 Diabetes. The companies which have their Type 1 Diabetes drug candidates in the most advanced stage, i.e preregistration include Provention Bio

Phases

This report covers around 100+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Type 1 Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Type 1 Diabetes: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Type 1 Diabetes therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Type 1 Diabetes drugs.

Type 1 Diabetes Report Insights

• Type 1 Diabetes Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Type 1 Diabetes Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Type 1 Diabetes drugs?
• How many Type 1 Diabetes drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Type 1 Diabetes?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Type 1 Diabetes therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Type 1 Diabetes and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Landos Biopharma
• Diamyd Medical
• Gan&Lee Pharmaceuticals
• Zealand Pharma
• Kamada
• AstraZeneca
• Novo Nordisk
• Provention Bio
• Histogen
• Vertex Pharmaceuticals
• Panbela Therapeutics
• Arecor
• Bioprojet
• Novartis
• ImCyse
• Adocia
• Anelixis Therapeutics
• Tolerion
• TikoMed
• Avotres
• REMD Biotherapeutics
• Novo Nordisk

Key Products

• LABP 111
• Autoimmune diabetes vaccine
• Insulin lispro biosimilar
• Dasiglucagon
• Alpha-1 antitrypsin
• Exenatide
• Dextran sulfate-low molecular weight
• TTP 399
• Teplizumab
• Emricasan
• VX 880
• Eflornithine oral
• Ultra-rapid acting insulin aspart
• Pitolisant
• Iscalimab
• IMCY 0098
• Insulin/pramlintide
• AT-1501
• TOL 3021
• AVT001
• Volagidemab
• NNC0363 0845

This product will be delivered within 1-3 business days.